What's Behind Guardant Health's Mixed Q2 Results
You might think that Guardant Health's (NASDAQ: GH) strong revenue growth in the first quarter and its multiple collaboration deals announced this year would have helped make the stock a big winner. But that's not the case. As of the market close on Thursday, Guardant Health was up only 6% year to date.
The liquid-biopsy pioneer announced its second-quarter results after the market close on Thursday. Was there enough good news to provide a nice catalyst for the healthcare stock? Here are the highlights from Guardant Health's Q2 update.
Image source: Getty Images.
Source Fool.com
